Gilead Letairis Will Be Available Through LEAP Restricted Distribution Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.